Back

To compare efficacy and safety of direct oral anticoagulants in patients with concurrent atrial fibrillation and bioprosthetic heart valve repair or replacement: a systematic review and meta-analysis

28 August 2022 (08:15 - 08:45)
Organised by:
Congress Presentation Part of: Thrombosis and anticoagulation in valvular heart disease Prosthetic Heart Valves ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Arpanjeet Kaur

Icahn School of Medicine at Mount Sinai Morningside West, New York City (United States of America)

4 More presentations in this session

Presentation thumbnail
Oral anticoagulant treatment in patients with atrial fibrillation early after valvular intervention: a nationwide cohort study
Associate Professor C. Christersson (Uppsala, SE)
Abstract Slides
Presentation thumbnail
Comparing direct oral anticoagulants versus vitamin k antagonist in patients with atrial fibrillation after transcatheter aortic valve replacement: an updated meta-analysis
Doctor A. Kaur (New York City, US)
Abstract Slides
Presentation thumbnail
Risk factors and clinical effects of late leaflet thrombosis after transcatheter aortic valve replacement
Doctor M. Bak (Seoul, KR)
Abstract Slides
Presentation thumbnail
Hypoattenuated leaflet thickening is associated with silent brain injury
Doctor A. Nagy (Budapest, HU)
Abstract Slides

Access the full session

Session thumbnail
Thrombosis and anticoagulation in valvular heart disease

The Event

Event poster

ESC Congress 2022

28 August 2022 08:15 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources